Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikaël J Pittet

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 6, 2004
Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoringDaniel E Speiser, Mikaël J Pittet, Philippe Guillaume, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2004
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivoMei-Ling Chen, Mikaël J Pittet, Leonid Gorelik, et al.
European Journal of Immunology|March 1, 2002
In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cellsDaniel E Speiser, Danielle Liénard, Mikaël J Pittet, et al.
Seminars in Cancer Biology|March 6, 2004
Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cellsDaniel E Speiser, Mikaël J Pittet, Donata Rimoldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1Maha Ayyoub, Alfred Zippelius, Mikaël J Pittet, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cellsMikaël J Pittet, Verena Rubio-Godoy, Gilles Bioley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2007
Four functionally distinct populations of human effector-memory CD8+ T lymphocytesPedro Romero, Alfred Zippelius, Isabel Kurth, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 11, 2024
Pharmacological Polarization of Tumor-Associated Macrophages Toward a CXCL9 Antitumor PhenotypeNoah Enbergs, Elias A Halabi, Anne-Gaëlle Goubet, et al.
Blood|February 28, 2002
Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cellsTessa C C Kerre, Greet De Smet, Magda De Smedt, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 6, 2024
Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor SizesBenan Kartal, Christopher S Garris, Hyung Shik Kim, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 6, 2004
Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoringDaniel E Speiser, Mikaël J Pittet, Philippe Guillaume, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2004
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivoMei-Ling Chen, Mikaël J Pittet, Leonid Gorelik, et al.
European Journal of Immunology|March 1, 2002
In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cellsDaniel E Speiser, Danielle Liénard, Mikaël J Pittet, et al.
Seminars in Cancer Biology|March 6, 2004
Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cellsDaniel E Speiser, Mikaël J Pittet, Donata Rimoldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1Maha Ayyoub, Alfred Zippelius, Mikaël J Pittet, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cellsMikaël J Pittet, Verena Rubio-Godoy, Gilles Bioley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2007
Four functionally distinct populations of human effector-memory CD8+ T lymphocytesPedro Romero, Alfred Zippelius, Isabel Kurth, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 11, 2024
Pharmacological Polarization of Tumor-Associated Macrophages Toward a CXCL9 Antitumor PhenotypeNoah Enbergs, Elias A Halabi, Anne-Gaëlle Goubet, et al.
Blood|February 28, 2002
Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cellsTessa C C Kerre, Greet De Smet, Magda De Smedt, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 6, 2024
Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor SizesBenan Kartal, Christopher S Garris, Hyung Shik Kim, et al.
Pageof 3